Plain-English translation of NCT05730205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether Nexplanon, a small hormonal implant placed under the skin of your arm, can help reduce the frequency and severity of pain crises in women with sickle cell disease. The medication releases a steady hormone that may help prevent the vaso-occlusive crises (episodes of severe pain) that are common with sickle cell disease. Researchers want to measure how this treatment affects your pain episodes, quality of life, and blood health.
Women with sickle cell disease need reliable contraception, and hormonal birth control has shown promise in reducing pain crises in some patients. This study exists to see whether this medication can be an effective option that both prevents pregnancy and helps manage the painful complications of sickle cell disease.
You would participate in two phases lasting about 9 months total. First, you'll have a 3-month observation period where you won't use any hormonal contraception (you would need to use barrier methods, be abstinent, or have a permanent contraception method). Then, you'll have the hormonal implant placed under your skin for 6 months. Throughout both phases, you'll track your pain episodes using text messages on your phone and complete visits to measure how the treatment is working.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Pennsylvania
Enrollment target
~22 participants
Started
August 2023
Primary completion
March 2027
Age range
18 Years – 45 Years
Sex
Female only
Last updated on clinicaltrials.gov in June 2026.